[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607936":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":22,"studyPopulation":22,"armGroups":29,"interventions":36,"overallOfficials":42,"centralContacts":22,"locations":46,"responsibleParty":66,"collaborators":22,"id":69,"slug":22,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":22,"eligibilityCriteria":73,"healthyVolunteers":70,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":22,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":49,"whyStopped":22,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Children's Mercy Hospital Kansas City","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":22},[9,13],{"measure":10,"description":11,"timeFrame":12},"Number of participants who experience adverse reactions to the measles, mumps, and rubella vaccination","Patients will be screened for adverse reactions following vaccine administration","Between 0-240 days after vaccine administration",{"measure":14,"description":15,"timeFrame":16},"Number of participants with resultant initial seropositivity against measles after vaccination","Serologic response will be measured after vaccine administration.","Between 60-240 days after vaccine administration.",[18],{"measure":19,"description":20,"timeFrame":21},"Number of participants who experience prolonged seropositivity after vaccine administration","Serologic response will be tested at least 365 days after final vaccine administration","Minimum of 365 days after vaccine administration",null,{"allocation":24,"interventionModel":25,"interventionModelDescription":22,"primaryPurpose":26,"observationalModel":22,"timePerspective":22,"maskingInfo":27},"NA","SINGLE_GROUP","PREVENTION",{"masking":28,"maskingDescription":22,"whoMasked":22},"NONE",[30],{"label":31,"type":32,"description":33,"interventionNames":34},"Measles, Mumps, Rubella Vaccination","EXPERIMENTAL","Patients receiving MMR vaccination due to no historical vaccine OR a seronegativity for measles",[35],"Drug: Commercial measles, mumps, and rubella (MMR) vaccine",[37],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":22},"DRUG","Commercial measles, mumps, and rubella (MMR) vaccine","Participants will receive the commercial MMR vaccine if they are deemed eligible for the study.",[31],[43],{"name":44,"affiliation":5,"role":45},"Victoria Blazek, PharmD, BCPPS","PRINCIPAL_INVESTIGATOR",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Children's Mercy Hospital","RECRUITING","Kansas City","Missouri","64108","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-94.57857,39.09973,{"lat":59,"lon":58},[62],{"name":44,"role":63,"phone":64,"phoneExt":22,"email":65},"CONTACT","816-302-3724","vmblazek@cmh.edu",{"type":45,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"Victoria Blazek","Clinical Pharmacy Specialist","100607936",false,"NCT07195032","Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients","Inclusion Criteria:\n\n* Received a heart transplant\n* At least 1 year after transplant\n* At least 1 year after antibody-mediated rejection treatment (intravenous immune globulin, rituximab, bortezomib, plasmapheresis, carfilzomib, eculizumab, daratumumab)\n* At least 1 year from anti-thymocyte globulin\n* At least 6 months after pulse dose steroid treatment or basiliximab treatment\n* No history of MMR vaccination OR History of MMR vaccination but seronegativity for measles at time of inclusion\n* Clinically well\n\nExclusion Criteria:\n\n* History of repeated infections necessitating adjustment in immunosuppression to non-standard regimen, including single agent immunosuppression and modified trough levels.\n* History of anaphylactic reaction to MMR vaccination","ALL","1 Year","17 Years",{"count":78,"type":79},60,"ESTIMATED","INTERVENTIONAL",[82],"PHASE4","The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission\u002Fassent will receive the commercial MMR vaccine according to product indication and labeling.",[85],"Heart Transplant Infection Prevention",[87,88,89,90,91],"Measles","Mumps","Rubella","Live vaccine","Heart transplant","2025-09-19",{"date":94,"type":95},"2025-09-26","ACTUAL",{"date":97,"type":95},"2025-09-11",{"date":99,"type":79},"2027-09-11",{"name":5,"class":6},1]